Leukemia

Stephen Schuster, MD, explained how Penn Medicine is utilizing at-home treatments, which will continue after the pandemic, to maximize safety and reduce hospital traffic during the COVID-19 pandemic.

A study found that dexrazoxane, a cardioprotective drug, preserved cardiac function without compromising overall survival and event-free survival for pediatric patients with acute myeloid leukemia.

Stephen Schuster, MD, of Penn Medicine discussed testing for COVID-19, telemedicine and how they are adjusting their treatment of patients with aggressive lymphomas during the pandemic.

Test your diagnostic knowledge with this month's Image IQ.

Researchers found that a high dose of CAR T-19 may be more effective than a low dose at inducing a complete response without excessive toxicity.

Researchers found that 2 studied strategies, which combined nivolumab and doxorubicin, vinblastine, and dacarbazine, are feasible, highly effective, and result in excellent 12-month progression-free survival.

SGX301 is being evaluated for the treatment of patients with early-stage cutaneous T-cell lymphoma in the pivotal phase III FLASH study, which demonstrated that continued treatment twice weekly for 12 weeks increased the positive response rate.

In this study, the feasibility and safety of DETECT-A coupled with PET-CT imaging to detect cancer was evaluated using a prospective, interventional study of 10,006 women not previously known to have cancer.

This study found that the consumption of antioxidants through dietary intake was correlated with reduced rates of infection or mucositis, with no increased risk of relapse or reduced survival.

The phase III UNITY-CLL trial evaluating the combination of umbralisib plus ublituximab met its primary endpoint at a prespecified interim analysis and will be stopped early for superior efficacy.

The first-in-human clinical trial for TruUCAR GC027 in relapsed or refractory T-cell acute lymphoblastic leukemia was announced by Gracell Biotechnologies.

Hypercalcemia at diagnosis of diffuse large B-cell lymphoma was found to be strongly correlated with adverse prognostic factors and a short diagnosis-to-treatment interval.

The FDA granted orphan drug designation to Ascentage Pharma’s HQP1351 for the treatment of chronic myeloid leukemia.

The FDA granted priority review to a new drug application for CC-486 for the maintenance treatment of adult patients with acute myeloid leukemia based on efficacy and safety results from the pivotal phase III QUAZAR AML-001 study.

The ongoing trial is treating patients with relapsed or refractory CLL/SLL or NHL who failed or were intolerant to 2 or more lines of established therapy, or for whom no other treatment options are available.

The FDA granted regenerative medicine advanced therapy designation to tisagenlecleucel for an investigational new indication to treat patients with relapsed or refractory follicular lymphoma.

The FDA approved ibrutinib in combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

The International Lymphoma Radiation Oncology Group laid out a set of emergency recommendations for alternative radiation treatment schemes for treating patients with hematologic malignancies during the COVID-19 pandemic.

Researchers found that the potential availability of CAR T-cell therapies for large B-cell lymphomas with lower adverse event rates that are suitable for outpatient administration may reduce the total costs of care.

AstraZeneca announced it will be conducting a global clinical trial, CALAVI, to examine the impact of adding acalabrutinib to best supportive care for patients who are severely ill with the COVID-19 infection.

Michael L. Grossbard, MD, suggested that chemo-free regimens, including PI3K inhibitors and a more widespread use of allogeneic stem cell transplant, are being explored as treatment options in this space.

Researchers found that in patients with chronic lymphocytic leukemia receiving commercial ibrutinib, initial dose and dose modification during therapy did not appear to impact event-free survival or overall survival.

A 1-year follow-up of the phase II ZUMA-2 study found that KTE-X19 induced durable remissions in a majority of patients with relapsed or refractory mantle-cell lymphoma.

The FDA granted fast track designation to ME-401, an investigational selective oral inhibitor of PI3K delta, for the treatment of adult patients with relapsed or refractory follicular lymphoma.

Genentech recently announced their phase III study resulted in improved overall survival and composite complete remission rates for patients with previously untreated acute myeloid leukemia.